Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corp (NASDAQ: ABUS) generates news primarily through clinical trial updates, scientific conference presentations, and corporate milestones in its pursuit of hepatitis B virus (HBV) cure therapies. As a clinical-stage biopharmaceutical company, Arbutus regularly reports on the progress of its drug candidates through the development pipeline.
News coverage for Arbutus typically includes clinical trial data readouts for imdusiran and AB-101, the company's lead HBV drug candidates. Investors and researchers monitoring HBV therapeutic development follow these updates closely, as trial results shape understanding of whether combination approaches can achieve functional cure. Conference presentations at major hepatology meetings provide additional scientific detail beyond press releases.
Quarterly financial reports reveal the company's cash position and operating expenses, critical metrics for clinical-stage biotechs that rely on financing rather than product revenue. These reports often coincide with pipeline updates and forward-looking guidance on clinical timelines. Partnership announcements and licensing deals related to Arbutus's lipid nanoparticle (LNP) technology platform also generate coverage.
Regulatory interactions, including FDA communications and clinical trial design decisions, inform expectations about development pathways. Board and leadership changes affect corporate strategy and investor sentiment. For those tracking the competitive HBV cure landscape, Arbutus news provides insight into one focused player's progress toward transforming chronic infection treatment.
Bookmark this page to follow Arbutus Biopharma's clinical development progress and corporate updates as the company advances its hepatitis B cure programs.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its third quarter 2020 financial results, highlighting progress in its Phase 1a/1b clinical trial for AB-729, an RNAi therapeutic for chronic hepatitis B virus (HBV). AB-729 showed significant reductions in HBsAg with a favorable safety profile. The company had cash reserves of $118.3 million, sufficient to fund operations into mid-2022. Despite a net loss of $21.8 million for the quarter, this is an improvement from the previous year's loss. The clinical collaboration with Assembly Biosciences is set to evaluate AB-729 in combination therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its Q3 2020 financial results and corporate update on November 5, 2020. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through Arbutus' website, and a recorded version will be available afterward. The company focuses on developing a cure for chronic hepatitis B and treatments for coronaviruses, including COVID-19. For further details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced participation in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on October 20, 2020, at 10:00 am ET. The presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), David Hastings (CFO), and Michael McElhaugh (CBO). The live webcast can be accessed on Arbutus' website, with an archived replay available post-conference. Arbutus is focused on developing a cure for chronic hepatitis B virus (HBV) infection and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma (Nasdaq: ABUS) will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include President and CEO William Collier, Chief Scientific Officer Dr. Michael Sofia, Chief Development Officer Dr. Gaston Picchio, and Chief Financial Officer David Hastings. The event will be accessible via webcast on the company’s investor website, with a replay available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include William Collier (President and CEO), Dr. Michael Sofia (Chief Scientific Officer), Dr. Gaston Picchio (Chief Development Officer), and David Hastings (Chief Financial Officer). The chat will be accessible via a live webcast on Arbutus' website, with an archived replay available post-conference. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports favorable results from ongoing Phase 1a/1b clinical trials for its RNAi drug AB-729 targeting chronic hepatitis B virus (HBV) infection. A single 90 mg dose showed a mean HBsAg reduction of 1.23 log10 IU/mL at week 12, indicating both efficacy and safety. The company continues to evaluate multiple dosing regimens, with results from 60 mg cohorts forthcoming. Over 250 million people are affected by HBV globally, showcasing a critical need for effective treatments.
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on curing chronic hepatitis B virus (HBV) infection and developing therapies for coronaviruses, will participate in a virtual fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 am ET.
Key presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), and David Hastings (CFO). The live webcast will be accessible on Arbutus' website and will feature a replay after the event.
Assembly Biosciences and Arbutus Biopharma have partnered to conduct a clinical trial evaluating the combination of Assembly's ABI-H0731 and Arbutus' AB-729 for treating chronic hepatitis B virus (HBV) infection. This Phase 2 trial aims to assess safety, pharmacokinetics, and antiviral activity among 60 patients over 48 weeks. The collaboration is expected to enhance therapeutic options for HBV and address the significant unmet medical need in this area, given HBV's global prevalence affecting over 250 million people.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has reported progress in its clinical trials and has provided a corporate update. The Phase 1a/1b trial for AB-729, an RNAi agent targeting chronic hepatitis B, is on track, with results from new cohorts expected in the latter half of 2020. The company also anticipates completing IND-enabling studies for AB-836, an oral HBV capsid inhibitor, by year-end. Financially, they hold $84 million in cash, with guidance extended through mid-2022. Net loss for Q2 2020 was $17.1 million, a decrease from $26.1 million in Q2 2019.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has scheduled its Q2 2020 financial results and conference call for August 7, 2020. The press release will be issued at 7:30 a.m. ET, followed by the conference call/webcast at 8:45 a.m. ET. Live access to the call can be found on Arbutus' website, with an archived version available afterward. Arbutus focuses on developing a cure for chronic hepatitis B virus infections and treatments for coronaviruses, including COVID-19. For more details, visit www.arbutusbio.com.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
